Biotech Values

[ghmm]

That trial actually is the one that is most a surprise to me. Even I have conceded Danoprevir+SOC reaching market being unlikely

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46800829&txt2find=191

I would have thought some small safety studies and then boosted Danoprevir in the INFORM direction as the likely direction.